Evidence map›Paper›PMID 35875883›Full record

ArticleCardiovascular research2023

Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases.

Mariann Gyöngyösi, Pilar Alcaide, Folkert W Asselbergs, Bianca J J M Brundel, Giovanni G Camici, Paula da Costa Martins, Péter Ferdinandy, Marianna Fontana, Henrique Girao, Massimiliano Gnecchi and 14 more

Open access · bronzeAbstract read
In one paragraph

Article in Cardiovascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 4 pooled it
19.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 4 syntheses or guidelines pooled it, 163 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Bridging Gaps in Long COVID Therapy: A Review.Current medicinal chemistry · 2026
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Effects of Cytokines (or Activating Factors) on Arterial Endothelial Cells.International journal of molecular sciences · 2025
    Review
  19. Review
  20. Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 20 institutions in 10 countries.

Mariann GyöngyösiDivision of Cardiology, 2nd Department of Internal Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Pilar AlcaideDepartment of Immunology, Tufts University School of Medicine, Boston, MA, USA.
Folkert W AsselbergsDepartment of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Bianca J J M BrundelDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
Giovanni G CamiciCenter for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
Paula da Costa MartinsDepartment of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0002-0695-1187
Péter FerdinandyDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Marianna FontanaDivision of Medicine, Royal Free Hospital London, University College London, London, UK.ORCID 0000-0002-9233-9831
Henrique GiraoCenter for Innovative Biomedicine and Biotechnology (CIBB), Clinical Academic Centre of Coimbra (CACC), Faculty of Medicine, Univ Coimbra, Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal.ORCID 0000-0002-5786-8447
Massimiliano GnecchiDepartment of Molecular Medicine, Unit of Cardiology, University of Pavia, Pavia, Italy.ORCID 0000-0001-7435-4328
Can Gollmann-TepeköylüDepartment of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Petra KleinbongardInstitut für Pathophysiologie, Westdeutsches Herz- und Gefäßzentrum, Universitätsklinikum Essen, Essen, Germany.ORCID 0000-0003-3576-3772
Thomas KriegDepartment of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.ORCID 0000-0002-5192-580X
Rosalinda MadonnaDepartment of Pathology, Institute of Cardiology, University of Pisa, Pisa, Italy.
Melanie PaillardLaboratoire CarMeN-équipe IRIS, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, Univ-Lyon, 69500 Bron, France.
Antonis PantazisNational Heart and Lung Institute, Imperial College London, London, UK.
Cinzia PerrinoDepartment of Advanced Biomedical Sciences, Federico II University, Via Pansini 5, 80131 Naples, Italy.ORCID 0000-0002-2274-0048
Maurizio PesceUnità di Ingegneria Tissutale cardiovascolare, Centro Cardiologico Monzino, IRCCS, Milan, Italy.ORCID 0000-0002-3097-8961
Gabriele G SchiattarellaDivision of Cardiology, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
Joost P G SluijterLaboratory of Experimental Cardiology, Cardiology, UMC Utrecht Regenerative Medicine Center, Utrecht, The Netherlands.ORCID 0000-0003-2088-9102
Sabine SteffensInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.ORCID 0000-0002-6892-9751
Carsten TschöpeBerlin Institute of Health (BIH) at Charité, Universitätmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK), Partner site Berlin and Dept Cardiology (CVK), Charité, Berlin, Germany.
Sophie Van LinthoutBerlin Institute of Health (BIH) at Charité, Universitätmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK), Partner site Berlin and Dept Cardiology (CVK), Charité, Berlin, Germany.ORCID 0000-0002-7581-7870
Sean M DavidsonThe Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, WC1E 6HX London, UK.
Berlin Institute of Health at Charité - Universitätsmedizin Berlin · DEUtrecht University · NLAmsterdam University Medical Centers · NLCentro Cardiologico Monzino · ITEssen University Hospital · DEFederico II University Hospital · ITGerman Centre for Cardiovascular Research · DEHarefield Hospital · GBInnsbruck Medical University · ATMaastricht University · NLMax Delbrück Center · DEMedical University of Vienna · ATSemmelweis University · HUThe Royal Free Hospital · GBTufts University · USUniversité Claude Bernard Lyon 1 · FRUniversity College London · GBUniversity of Cambridge · GBUniversity of Coimbra · PTUniversity of Pavia · IT

Funding

Mechanisms of T cell activation in cardiac fibrosis and non-ischemic heart failureR01HL144477 · NHLBI · TUFTS UNIVERSITY BOSTON · PI ALCAIDE ALONSO, MARIA PILAR · 2019 to 2023
$3.2M
British Heart Foundation PG/16/85/32471British Heart Foundation PG/19/51/34493European Research Council 725229NHLBI NIH HHS R01 HL144477
6 · The paper itself

Abstract

Long COVID has become a world-wide, non-communicable epidemic, caused by long-lasting multiorgan symptoms that endure for weeks or months after SARS-CoV-2 infection has already subsided. This scientific document aims to provide insight into the possible causes and therapeutic options available for the cardiovascular manifestations of long COVID. In addition to chronic fatigue, which is a common symptom of long COVID, patients may present with chest pain, ECG abnormalities, postural orthostatic tachycardia, or newly developed supraventricular or ventricular arrhythmias. Imaging of the heart and vessels has provided evidence of chronic, post-infectious perimyocarditis with consequent left or right ventricular failure, arterial wall inflammation, or microthrombosis in certain patient populations. Better understanding of the underlying cellular and molecular mechanisms of long COVID will aid in the development of effective treatment strategies for its cardiovascular manifestations. A number of mechanisms have been proposed, including those involving direct effects on the myocardium, microthrombotic damage to vessels or endothelium, or persistent inflammation. Unfortunately, existing circulating biomarkers, coagulation, and inflammatory markers, are not highly predictive for either the presence or outcome of long COVID when measured 3 months after SARS-CoV-2 infection. Further studies are needed to understand underlying mechanisms, identify specific biomarkers, and guide future preventive strategies or treatments to address long COVID and its cardiovascular sequelae.

Indexed as

COVID-19Heart DiseasesCOVID-19 TestingHeartHumansMyocardiumPost-Acute COVID-19 SyndromeSARS-CoV-2CardiacCardiovascularCOVID-19Long COVIDPost COVID

Identifiers

PMID35875883
PMCPMC9384470
OpenAlexW4287147169

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.